CY1106669T1 - Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης - Google Patents

Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης

Info

Publication number
CY1106669T1
CY1106669T1 CY20071100827T CY071100827T CY1106669T1 CY 1106669 T1 CY1106669 T1 CY 1106669T1 CY 20071100827 T CY20071100827 T CY 20071100827T CY 071100827 T CY071100827 T CY 071100827T CY 1106669 T1 CY1106669 T1 CY 1106669T1
Authority
CY
Cyprus
Prior art keywords
immunity
mycoplasma hyopneumoniae
improved
bacterin
infection
Prior art date
Application number
CY20071100827T
Other languages
English (en)
Inventor
Hsien-Jue Chu (Steve)
Wumin Li
Zhichang Xu
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22972978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106669(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth filed Critical Wyeth
Publication of CY1106669T1 publication Critical patent/CY1106669T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Abstract

Η εφεύρεση παρέχει βελτιωμένο σκεύασμα εμβολίου βακτηρίνης Mycoplasma hyopneumoniae, το οποίο παρέχει κατά πλεονεκτικό τρόπο ανοσία από μόλυνση μετά από μια μοναδική χορήγηση. Το σκεύασμα περιέχει μια απενεργοποιημένη βακτηρίνη Mycoplasma hyopneumoniae κι ένα ανοσοενισχυτικό μίγμα, τα οποία, συνδυασμένα, παρέχουν ανοσία από μόλυνση από Mycoplasma hyopneumoniae μετά από μια μοναδική χορήγηση, και προκαλούν ανοσοαπόκριση εξειδικευμένη έναντι βακτηρίνης Mycoplasma hyopneumoniae συμπεριλαμβανομένης κυτταρικής ανοσίας και τοπικής (εκκριτικής IgA) ανοσίας. Σε μια προτιμούμενη εφαρμογή, το ανοσοενισχυτικό μίγμα περιέχει ένα πολυμερές ακρυλικού οξέος, προτιμότερα Carbopol, κι ένα μίγμα ενός μεταβολίσιμου ελαίου όπως ενός ή περισσότερων ακόρεστων τερπενικών υδρογονανθράκων, κατά προτίμηση σκουαλενίου ή σκουαλανίου, κι ενός συμπολυμερούς κατά συστάδες πολυοξυαιθυλενίου-πολυπροπυλενίου όπως Pluronic®. Το σκεύασμα εμβολίου μπορεί προαιρετικώς να περιέχει ένα συντηρητικό, κατά προτίμηση thimerosal και/ή EDTA.
CY20071100827T 2000-12-19 2007-06-21 Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης CY1106669T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25663700P 2000-12-19 2000-12-19
PCT/US2001/047865 WO2002049666A2 (en) 2000-12-19 2001-12-11 Mycoplasma hyopneumoniae bacterin vaccine

Publications (1)

Publication Number Publication Date
CY1106669T1 true CY1106669T1 (el) 2012-05-23

Family

ID=22972978

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100827T CY1106669T1 (el) 2000-12-19 2007-06-21 Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης

Country Status (28)

Country Link
US (4) US20020131980A1 (el)
EP (1) EP1343525B1 (el)
JP (2) JP5074656B2 (el)
KR (1) KR100874119B1 (el)
CN (1) CN1296095C (el)
AR (1) AR033410A1 (el)
AT (1) ATE359813T1 (el)
AU (2) AU2002228993B2 (el)
BG (1) BG66213B1 (el)
BR (1) BRPI0116249B1 (el)
CY (1) CY1106669T1 (el)
CZ (1) CZ307075B6 (el)
DE (1) DE60127994T2 (el)
DK (1) DK1343525T3 (el)
ES (1) ES2283452T3 (el)
HK (1) HK1056513A1 (el)
HR (1) HRP20030585B1 (el)
HU (1) HU227431B1 (el)
ME (1) ME00570B (el)
MX (1) MXPA03005357A (el)
MY (1) MY129765A (el)
NZ (1) NZ526904A (el)
PL (1) PL211174B1 (el)
PT (1) PT1343525E (el)
RS (1) RS51536B (el)
TW (1) TWI308872B (el)
WO (1) WO2002049666A2 (el)
ZA (1) ZA200305545B (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
HUE054868T2 (hu) 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
DK2371383T3 (en) 2005-12-29 2015-11-30 Boehringer Ingelheim Vetmed Use of a PCV2 immunogenic composition for reduction of clinical symptoms in pigs
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
RU2520087C2 (ru) 2006-12-15 2014-06-20 Бёрингер Ингельхайм Ветмедика, Инк. Лечение свиней с помощью антигена pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
MX2010005014A (es) 2007-11-06 2010-06-30 Wyeth Llc Vacuna viva avirulenta de mycoplasma hyopneumoniae con adyuvante.
US20090317423A1 (en) 2008-01-23 2009-12-24 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US8444989B1 (en) * 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
EP2291194B1 (en) * 2008-06-25 2017-02-22 Braasch Biotech LLC Compositions and methods for enhanced somatostatin immunogenicity
MX2011012362A (es) * 2009-05-19 2012-04-19 Bioproperties Pty Ltd Cepa de vacuna de mycoplasma hyopneumoniae sensible a la temperatura y usoz de la misma.
CN102448488B (zh) 2009-06-04 2014-10-15 独立行政法人产业技术综合研究所 支原体感染症用疫苗
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
KR101746880B1 (ko) * 2009-09-10 2017-06-14 메리얼 인코포레이티드 사포닌-함유 면역보강제를 포함하는 신규 백신 제형
WO2011136738A1 (en) 2010-04-30 2011-11-03 Temasek Life Sciences Laboratory Limited Universal vaccine against h5n1 lineages
US20150086587A1 (en) * 2012-03-28 2015-03-26 Kansas State University Research Foundation Vaccine adjuvant
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
CN103623400B (zh) * 2012-08-24 2016-08-17 普莱柯生物工程股份有限公司 抗猪支原体肺炎、传染性胸膜肺炎疫苗组合物及制备方法
EP2938356B1 (en) * 2012-12-28 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Immunogenic composition comprising mycoplasma antigens
CN104968365B (zh) 2012-12-28 2018-04-03 勃林格殷格翰动物保健有限公司 支原体疫苗的制备方法
CN104338128B (zh) * 2013-07-31 2017-09-05 普莱柯生物工程股份有限公司 一种疫苗组合物及其制备方法和应用
EA035265B1 (ru) 2013-10-02 2020-05-21 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Вариант белка opc2 pcv2 и содержащие его вирусоподобные частицы
US11883476B2 (en) * 2017-12-04 2024-01-30 Intervet Inc. Canine lyme disease vaccine
CN108324941A (zh) * 2018-04-03 2018-07-27 林淑卿 猪疾病疫苗用佐剂及其制备方法
CN117100851A (zh) * 2023-10-23 2023-11-24 成都依思康生物科技有限公司 一种佐剂、疫苗组合物及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) * 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3790665A (en) * 1968-02-23 1974-02-05 Haver Lockhart Labor Inc Injectable adjuvant,method of preparing same and compositions including such adjuvant
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
EP0283085B1 (en) 1987-03-17 1992-11-11 Akzo N.V. Adjuvant mixture
ES2052674T3 (es) * 1987-11-03 1994-07-16 Syntex Inc Adyuvante de vacunas.
US5240706A (en) * 1989-04-07 1993-08-31 Ml Technology Ventures, L.P. Intranasal administration of Mycoplasma hyopneumoniae antigen
EP0597852B2 (en) 1990-05-29 2005-08-10 Wyeth Holdings Corporation Swine pneumonia vaccine and method for the preparation thereof
US6113916A (en) * 1990-05-29 2000-09-05 American Cyanamid Company Method of enhancing cell mediated immune responses
US5695769A (en) * 1990-06-13 1997-12-09 Pfizer Inc. Pasteurella multocida toxoid vaccines
US5565205A (en) 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
US5616328A (en) 1991-11-15 1997-04-01 Pfizer Inc. Method of preparing gram-negative bacterial vaccines
US5338543A (en) * 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
US5534256A (en) * 1992-07-02 1996-07-09 University Of Saskatchewan Haemophilus somnus outer membrane protein extract enriched with iron-regulated proteins
JP3265095B2 (ja) * 1993-11-19 2002-03-11 本田技研工業株式会社 キャニスタ
DE69535520T2 (de) * 1994-05-10 2008-02-07 Wyeth Abgeänderter, verbesserter BRSV Lebend- Impfstoff
US5820869A (en) * 1995-06-07 1998-10-13 American Home Products Corporation Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection
DE19601754A1 (de) * 1996-01-19 1997-07-24 Hoechst Ag Dictyocaulus viviparus Antigen zur Diagnose des Lungenwurmbefalls und zur Vakzinierung
US5846735A (en) * 1996-04-18 1998-12-08 University Of Iowa Research Foundation Hepatitis C virus Fc-binding function
AU746442B2 (en) * 1996-12-20 2002-05-02 Board Of Regents, The University Of Texas System UspA1 and UspA2 antigens of Moraxella catarrhalis
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
US6342231B1 (en) * 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
US6632439B2 (en) * 1999-09-29 2003-10-14 Novartis Animal Health, Inc. Fusobacterium necrophorum vaccine and method for making such vaccine
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en) * 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
ATE412426T2 (de) * 2001-07-02 2008-11-15 Pfizer Prod Inc Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i
US20050220880A1 (en) * 2002-03-07 2005-10-06 Lewis Andrew L Drug carriers comprising amphiphilic block copolymers
ITMI20030269A1 (it) * 2003-02-14 2004-08-15 Advance Holdings Ltd Sale di cetilpiridino di un agente antiinfiammatorio
US8052762B1 (en) * 2010-09-02 2011-11-08 Kelly Van Gogh, LLC Compositions for dyeing keratin-containing fibers

Also Published As

Publication number Publication date
EP1343525A2 (en) 2003-09-17
US20020131980A1 (en) 2002-09-19
HUP0400687A2 (hu) 2004-06-28
CZ307075B6 (cs) 2018-01-03
AR033410A1 (es) 2003-12-17
KR20030065556A (ko) 2003-08-06
EP1343525B1 (en) 2007-04-18
HU227431B1 (en) 2011-06-28
US20120213816A1 (en) 2012-08-23
RS51536B (sr) 2011-06-30
CN1489472A (zh) 2004-04-14
US7666439B2 (en) 2010-02-23
DE60127994T2 (de) 2008-01-17
CN1296095C (zh) 2007-01-24
HRP20030585B1 (en) 2008-03-31
HRP20030585A2 (en) 2005-06-30
NZ526904A (en) 2005-07-29
PL211174B1 (pl) 2012-04-30
KR100874119B1 (ko) 2008-12-15
WO2002049666A2 (en) 2002-06-27
JP2009073855A (ja) 2009-04-09
HUP0400687A3 (en) 2004-10-28
BRPI0116249B1 (pt) 2016-06-14
ES2283452T3 (es) 2007-11-01
BR0116249A (pt) 2004-03-02
JP2004518655A (ja) 2004-06-24
US20100119471A1 (en) 2010-05-13
US20070020296A1 (en) 2007-01-25
BG107898A (bg) 2004-08-31
ZA200305545B (en) 2004-10-18
PT1343525E (pt) 2007-07-12
ME00570A (en) 2011-12-20
ATE359813T1 (de) 2007-05-15
HK1056513A1 (en) 2004-02-20
MY129765A (en) 2007-04-30
DE60127994D1 (de) 2007-05-31
AU2002228993B2 (en) 2006-06-29
YU49303A (sh) 2006-08-17
BG66213B1 (bg) 2012-05-31
DK1343525T3 (da) 2007-06-04
ME00570B (me) 2011-12-20
TWI308872B (en) 2009-04-21
US8187588B2 (en) 2012-05-29
AU2899302A (en) 2002-07-01
MXPA03005357A (es) 2003-10-06
WO2002049666A3 (en) 2003-02-06
US9238065B2 (en) 2016-01-19
JP5074656B2 (ja) 2012-11-14
CZ20031721A3 (cs) 2004-04-14
PL363220A1 (en) 2004-11-15

Similar Documents

Publication Publication Date Title
CY1106669T1 (el) Βελτιωμενο i mycoplasma hy opneumoniae/ i εμβολιο βακτηρινης
RS99704A (en) Improved mycoplasma hyopneumoniae bacterin vaccine
AR026940A1 (es) Composicion farmaceuticas para modulacion inmunologica y preparacion de vacunas
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
ES2149361T3 (es) Vacuna viva modificada contra el brsv, mejorada.
LU91778I2 (fr) Menveo - vaccin méningococcique des groupes A,C, W135 et Y conjugué.
CY1117957T1 (el) Συμπληρωμενο omv εμβολιο εναντι μηνιγγιοκοκκου
NO20091022L (no) Vaksine omfattende en olje i vann emulsjons-adjuvant
CY1108526T1 (el) Εμβολια εναντι καρκινων
ATE392216T1 (de) Mycobakterieller impfstoff
DK1259259T3 (da) Mucosal adjuvansformulering
BR0111834A (pt) Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
WO2002010343A3 (en) Temperature-sensitive live vaccine for mycoplasma hyopneumoniae
CO5660272A2 (es) Vacunas bovinas con adyuvantes
DK0757556T3 (da) Borrelia Burgdorferi-bakterin
DE60036705D1 (de) Adjuvanskombinationen zur immunisierung und vakzine
AR111910A2 (es) Composición inmunogénica que comprende una formulación de adyuvante, composición de vacuna, procedimiento, usos, métodos
SE9600646D0 (sv) Vaccin
CY1114624T1 (el) Εμβολιο δυτικου νειλου